Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noman Paracha

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Health and Quality of Life Outcomes|September 14, 2018
Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patientsNoman Paracha, Ahmed Abdulla, Katherine S MacGilchrist
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Accounting for Uncertainty in Decision Analytic Models Using Rank Preserving Structural Failure Time Modeling: Application to Parametric Survival ModelsIain Bennett, Noman Paracha, Keith Abrams, et al.
Pharmacoeconomics - Open|February 27, 2021
Mixture Cure Models in Oncology: A Tutorial and Practical GuidanceFederico Felizzi, Noman Paracha, Johannes Pöhlmann, et al.
Pharmacoeconomics|October 18, 2021
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)Noman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|February 26, 2022
Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)Noman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|December 15, 2021
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their CaregiversC Simone Sutherland, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|November 11, 2021
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy ManagementNoman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2011
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesotheliomaBeth Woods, Noman Paracha, David A Scott, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|August 31, 2016
Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic reviewNoman Paracha, Per-Olof Thuresson, Santiago G Moreno, et al.
Breast Cancer Research and Treatment|February 27, 2020
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysisNoman Paracha, Adriana Reyes, Véronique Diéras, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Health and Quality of Life Outcomes|September 14, 2018
Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patientsNoman Paracha, Ahmed Abdulla, Katherine S MacGilchrist
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Accounting for Uncertainty in Decision Analytic Models Using Rank Preserving Structural Failure Time Modeling: Application to Parametric Survival ModelsIain Bennett, Noman Paracha, Keith Abrams, et al.
Pharmacoeconomics - Open|February 27, 2021
Mixture Cure Models in Oncology: A Tutorial and Practical GuidanceFederico Felizzi, Noman Paracha, Johannes Pöhlmann, et al.
Pharmacoeconomics|October 18, 2021
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)Noman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|February 26, 2022
Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)Noman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|December 15, 2021
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their CaregiversC Simone Sutherland, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|November 11, 2021
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy ManagementNoman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2011
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesotheliomaBeth Woods, Noman Paracha, David A Scott, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|August 31, 2016
Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic reviewNoman Paracha, Per-Olof Thuresson, Santiago G Moreno, et al.
Breast Cancer Research and Treatment|February 27, 2020
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysisNoman Paracha, Adriana Reyes, Véronique Diéras, et al.
Pageof 4